Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development.
about
Novel approaches to identify protective malaria vaccine candidatesPlasmodium falciparum erythrocyte invasion: combining function with immune evasionPlasmodium malaria and antimalarial antibodies in the first year of lifeMerozoite surface proteins in red blood cell invasion, immunity and vaccines against malariaPaths to a malaria vaccine illuminated by parasite genomicsMultiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasionP113 is a merozoite surface protein that binds the N terminus of Plasmodium falciparum RH5Different Regions of Plasmodium falciparum Erythrocyte-Binding Antigen 175 Induce Antibody Responses to Infection of Varied Efficacy.In vivo curative and protective potential of orally administered 5-aminolevulinic acid plus ferrous ion against malaria.Mining, visualizing and comparing multidimensional biomolecular data using the Genomics Data Miner (GMine) Web-Server.Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria.Immunity as a predictor of anti-malarial treatment failure: a systematic reviewAntibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum.Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria.Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease.Host age and expression of genes involved in red blood cell invasion in Plasmodium falciparum field isolates.Association of antibody responses to the conserved Plasmodium falciparum merozoite surface protein 5 with protection against clinical malariaStrategies for designing and monitoring malaria vaccines targeting diverse antigensSurface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates.Antibody response against three Plasmodium falciparum merozoite antigens in Mamuju District, West Sulawesi Province, Indonesia.Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.High yield purification of Plasmodium falciparum merozoites for use in opsonizing antibody assays.Comparative analysis of IgG responses to Plasmodium falciparum MSP1p19 and PF13-DBL1α1 using ELISA and a magnetic bead-based duplex assay (MAGPIX®-Luminex) in a Senegalese meso-endemic community.Research priorities for the development and implementation of serological tools for malaria surveillance.Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria.Immunization against a merozoite sheddase promotes multiple invasion of red blood cells and attenuates Plasmodium infection in mice.Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of responsePlasmodium falciparum clearance is rapid and pitting independent in immune Malian children treated with artesunate for malariaNew antigens for a multicomponent blood-stage malaria vaccineIdentification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide DisplayMalaria eradication and elimination: views on how to translate a vision into realityThe Structure of Plasmodium falciparum Blood-Stage 6-Cys Protein Pf41 Reveals an Unexpected Intra-Domain Insertion Required for Pf12 Coordination.Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communitiesAn Antibody Screen of a Plasmodium vivax Antigen Library Identifies Novel Merozoite Proteins Associated with Clinical Protection.Genetic Resistance to Malaria Is Associated With Greater Enhancement of Immunoglobulin (Ig)M Than IgG Responses to a Broad Array of Plasmodium falciparum Antigens.Biosignatures of Exposure/Transmission and ImmunityPlasmodium falciparum Protein Microarray Antibody Profiles Correlate With Protection From Symptomatic Malaria in KenyaComparative Antibody Responses Against three Antimalarial Vaccine Candidate Antigens from Urban and Rural Exposed Individuals in Gabon.Characterization of Inhibitors and Monoclonal Antibodies That Modulate the Interaction between Plasmodium falciparum Adhesin PfRh4 with Its Erythrocyte Receptor Complement Receptor 1.Longitudinal analysis of antibody responses in symptomatic malaria cases do not mirror parasite transmission in peri-urban area of Cote d'Ivoire between 2010 and 2013.
P2860
Q21131082-1A658C98-3B22-447C-8B64-709A3F11212EQ21131363-C67F4323-A7AC-430F-8788-66AD97BB2D25Q26315542-F32DBD27-E4A6-4197-9BF5-FB5E42F095F1Q26772878-91E3117C-83D3-4E48-A164-F2F9102F6908Q26853267-9E680242-85C3-4D6B-BEC3-A4E432377E66Q27230042-613646A7-E2C2-4A98-832F-209BDE09A662Q30042821-DCA19FC7-E25A-428B-BDA5-2A49AA27CCDAQ30386145-89515CCB-CDE6-4994-9156-A2FE78B01DBFQ30386961-1C56DA74-A69C-4585-9A55-835F5EA2A464Q31147151-F1B58CE0-9A88-4495-A196-7E9885B071B2Q31169310-2DFC0E53-BB1E-408A-8961-C1DE49FF75A4Q33582154-F0974267-6294-47A8-AE6F-2CC2B0E57886Q33636850-296B6E2F-300F-4B88-B27F-D79F5808BF9DQ33820897-CB18CB12-43EE-4928-81BC-8B7763B5C3F9Q33821137-180A4C3B-82CF-4E04-B9B4-1D32A9985C47Q33876022-3492E86A-D4AA-47EC-BA5B-4F1591C3F1FEQ33927906-E2DDCC04-929C-4BA4-AC8E-872177A010D5Q33959038-74DAAF22-0675-4216-80B0-641B6E999067Q34161839-523761C1-1230-4D56-8986-BD7AA0D758E2Q34320287-271679AB-B188-4A59-B00A-986B0A087D28Q34416904-6F5D706D-B8C4-41DC-8D3B-933D49F8319AQ34443423-681C6731-F7B6-42ED-B556-C35317F8C73FQ34460065-96DCBDC2-9FD1-4D0C-A7AC-3ED72A9B7A0EQ34500035-5363C4E7-53EE-4DFA-A474-87E8A9E515D0Q34515219-4C095D1A-22B9-45AD-BCBA-AA432BDB6804Q34591062-DAF322A2-0975-4BF8-BF39-30F96D2A7677Q34955461-4DF32420-DEF5-4318-BB48-AD7CF67F7F9EQ35102694-EFD21097-8E2A-4856-B6B3-FE968F95435AQ35216634-B9EEAE2A-371B-498C-98BB-FC7244693223Q35683634-3FA3DBE6-F434-4E8D-B3EC-E6CCE86C883AQ35712522-7B281A4E-F8F8-49BA-A273-B28D8E6C51E5Q35790481-D2A5B639-AE41-4C42-81ED-FAC02667AD69Q35961275-98FF87F8-0EEC-422E-87DE-0635499AD151Q36018397-2D0C7D1C-3008-4953-83D4-0D541F225233Q36042702-EB3ED0A3-8D69-4A65-BE10-78C984BB9A74Q36071335-4F491454-36F4-4360-89B9-43D5FA16607EQ36148976-9D2B1F5C-B6A1-4D04-B21A-159F61EE0087Q36226232-B5EC1492-F7CB-441B-989A-F203691A61A4Q36283289-7026BF99-F5D1-44AF-ADBB-283F4DD38632Q36292890-32226C04-B7A1-4C28-A028-64349BDCE3B1
P2860
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Identification and prioritizat ...... ine and biomarker development.
@en
type
label
Identification and prioritizat ...... ine and biomarker development.
@en
prefLabel
Identification and prioritizat ...... ine and biomarker development.
@en
P2093
P2860
P50
P921
P356
P1476
Identification and prioritizat ...... ine and biomarker development.
@en
P2093
Alex D Uboldi
Anthony N Hodder
Christine Langer
Christopher L King
Jennifer K Thompson
Julie Healer
Linda Reiling
Motomi Torii
Nadia Cross
Paul R Gilson
P2860
P304
P356
10.4049/JIMMUNOL.1300778
P407
P50
P577
2013-06-17T00:00:00Z